COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
Vitamin D study #22 of 50
9/25 Analysis of outcomes based on serum levels
Maghbooli et al., PLOS One, doi:10.1371/journal.pone.0239799 (Peer Reviewed)
Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection
Source   PDF   Share   Tweet
Retrospective 235 hospitalized patients showing a significant association between vitamin D sufficiency and reduction in clinical severity.
For patients over 40, mortality was 9.7% with 25(OH)D levels >30ng/mL, versus 20% for <30ng/mL.
A significant reduction in serum CRP, an inflammatory marker, along with increased lymphocytes percentage suggest that vitamin D sufficiency may help modulate the immune response possibly by reducing the risk for cytokine storm in response to this viral infection.

Maghbooli et al., 9/25/2020, retrospective, Iran, West Asia, peer-reviewed, 11 authors.
risk of death, 51.7% lower, RR 0.48, p = 0.08, treatment 7 of 72 (9.7%), control 27 of 134 (20.1%), age >40.
risk of ventilation, 31.6% lower, RR 0.68, p = 0.49, treatment 6 of 77 (7.8%), control 18 of 158 (11.4%).
risk of ICU admission, 32.0% lower, RR 0.68, p = 0.33, treatment 11 of 77 (14.3%), control 33 of 158 (20.9%), >30nmol/L.
Details of all 50 studies
Please submit corrections, updates, or comments.